BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533-9. [PMID: 32151618 DOI: 10.1016/j.jhep.2020.02.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Soriano V, Mendoza C, Barreiro P, Treviño A, Corral O. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol 2021;16:927-30. [PMID: 34406066 DOI: 10.2217/fmb-2021-0177] [Reference Citation Analysis]
2 Delphin M, Desmares M, Schuehle S, Heikenwalder M, Durantel D, Faure-Dupuy S. How to get away with liver innate immunity? A viruses' tale. Liver Int 2021;41:2547-59. [PMID: 34520597 DOI: 10.1111/liv.15054] [Reference Citation Analysis]
3 Nkongolo S, Hollnberger J, Urban S. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35028672 DOI: 10.1007/s00103-022-03486-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Osiowy C, Swidinsky K, Haylock-jacobs S, Sadler MD, Fung S, Wong D, Minuk GY, Doucette KE, Wong P, Tam E, Cooper C, Ramji A, Ma M, Nudo C, Tsoi K, Coffin CS. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100461] [Reference Citation Analysis]
5 Lucifora J, Michelet M, Salvetti A, Durantel D. Fast Differentiation of HepaRG Cells Allowing Hepatitis B and Delta Virus Infections. Cells 2020;9:E2288. [PMID: 33066405 DOI: 10.3390/cells9102288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
8 Lee AU, Lee C. Hepatitis D Review: Challenges for the Resource-Poor Setting. Viruses 2021;13:1912. [PMID: 34696341 DOI: 10.3390/v13101912] [Reference Citation Analysis]
9 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
10 Sandmann L, Cornberg M. Experimental Drugs for the Treatment of Hepatitis D. J Exp Pharmacol 2021;13:461-8. [PMID: 33889032 DOI: 10.2147/JEP.S235550] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore) 2021;100:e26571. [PMID: 34260535 DOI: 10.1097/MD.0000000000026571] [Reference Citation Analysis]
12 Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Reference Citation Analysis]
13 Kohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J. Human hepatitis D virus-specific T cell epitopes. JHEP Rep 2021;3:100294. [PMID: 34308324 DOI: 10.1016/j.jhepr.2021.100294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tseligka ED, Clément S, Negro F. HDV Pathogenesis: Unravelling Ariadne's Thread. Viruses 2021;13:778. [PMID: 33924806 DOI: 10.3390/v13050778] [Reference Citation Analysis]
15 Tong H, Wu Y, Yan Y, Dong Y, Guan X, Liu Y, Lu Z. No association between abortion and risk of breast cancer among nulliparous women: Evidence from a meta-analysis. Medicine (Baltimore) 2020;99:e20251. [PMID: 32384520 DOI: 10.1097/MD.0000000000020251] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Argirion I, Mahale P, Pfeiffer RM, Koshiol J, O'Brien TR. Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma. J Hepatol 2020;73:1583-4. [PMID: 32962868 DOI: 10.1016/j.jhep.2020.07.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
18 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
19 Ramos-Rincon JM, Pinargote H, Ramos-Belinchón C, de Mendoza C, Aguilera A, Soriano V. Hepatitis delta in patients hospitalized in Spain (1997-2018). AIDS 2021;35:2311-8. [PMID: 34261094 DOI: 10.1097/QAD.0000000000003024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Soriano V, Alvarez C, Edagwa B, de Mendoza C, Montoya N, Treviño A, Gendelman H. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis 2021;114:45-50. [PMID: 34728344 DOI: 10.1016/j.ijid.2021.10.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rizzetto M, Hamid S. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. Liver Int 2021;41:16-9. [DOI: 10.1111/liv.14729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200-1211. [PMID: 33484770 DOI: 10.1016/j.jhep.2021.01.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
23 Wedemeyer H. The burden of hepatitis D – defogging the epidemiological horizon. Journal of Hepatology 2020;73:493-5. [DOI: 10.1016/j.jhep.2020.06.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Soriano V, de Mendoza C, Treviño A, Ramos-Rincón JM, Moreno-Torres V, Corral O, Barreiro P. Treatment of Hepatitis Delta and HIV Infection. Liver Int 2022. [PMID: 35748639 DOI: 10.1111/liv.15345] [Reference Citation Analysis]
25 Papatheodoridi A, Papatheodoridis G. Hepatocellular carcinoma: the virus or the liver? Liver Int 2022. [PMID: 35319167 DOI: 10.1111/liv.15253] [Reference Citation Analysis]
26 Spearman CW, Dusheiko G, Jonas E, Abdo A, Afihene M, Cunha L, Desalegn H, Kassianides C, Katsidzira L, Kramvis A, Lam P, Lesi OA, Micah EA, Musabeyezu E, Ndow G, Nnabuchi CV, Ocama P, Okeke E, Rwegasha J, Shewaye AB, Some FF, Tzeuton C, Sonderup MW. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00041-3] [Reference Citation Analysis]
27 Lebossé F, Zoulim F. [Hepatitis B vaccine and liver cancer]. Bull Cancer 2021;108:90-101. [PMID: 33358507 DOI: 10.1016/j.bulcan.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Brancaccio G, Shanyinde M, Puoti M, Gaeta GB, Monforte AD, Vergori A, Rusconi S, Mazzarelli A, Castagna A, Antinori A, Cozzi-lepri A. Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. Pathogens and Global Health. [DOI: 10.1080/20477724.2022.2047551] [Reference Citation Analysis]
29 Papatheodoridi M, Papatheodoridis GV. Is hepatitis delta underestimated? Liver Int 2021;41 Suppl 1:38-44. [PMID: 34155795 DOI: 10.1111/liv.14833] [Reference Citation Analysis]
30 Baskiran A, Atay A, Baskiran DY, Akbulut S. Hepatitis B/D-Related Hepatocellular Carcinoma. A Clinical Literature Review. J Gastrointest Cancer 2021. [PMID: 34611832 DOI: 10.1007/s12029-021-00714-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
32 Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses 2021;13:830. [PMID: 34064419 DOI: 10.3390/v13050830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Mbaga DS, Kenmoe S, Kengne-Ndé C, Ebogo-Belobo JT, Mahamat G, Foe-Essomba JR, Amougou-Atsama M, Tchatchouang S, Nyebe I, Feudjio AF, Kame-Ngasse GI, Magoudjou-Pekam JN, Fokou LKM, Meta-Djomsi D, Maïdadi-Foudi M, Touangnou-Chamda SA, Daha-Tchoffo AG, Selly-Ngaloumo AA, Nayang-Mundo RA, Yéngué JF, Taya-Fokou JB, Kenfack-Momo R, Atembeh Noura E, Demeni Emoh CP, Tazokong HR, Bowo-Ngandji A, Sake CS, Atenguena Okobalemba E, Njiki Bikoi J, Njouom R, Riwom Essama SH. Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders. PLoS One 2022;17:e0262903. [PMID: 35061846 DOI: 10.1371/journal.pone.0262903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
35 Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
36 Tibiri A, Boria S, Traoré TK, Ouédraogo N, Nikièma A, Ganaba S, Compaoré JM, Ouédraogo I, Guissou IP, Carraz M. Countrywide Survey of Plants Used for Liver Disease Management by Traditional Healers in Burkina Faso. Front Pharmacol 2020;11:563751. [PMID: 33597863 DOI: 10.3389/fphar.2020.563751] [Reference Citation Analysis]
37 Niro GA, Ferro A, Cicerchia F, Brascugli I, Durazzo M. Hepatitis delta virus: From infection to new therapeutic strategies. World J Gastroenterol 2021; 27(24): 3530-3542 [PMID: 34239267 DOI: 10.3748/wjg.v27.i24.3530] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]